Smart cell delivery to target and control combination treatments for Alzheimer's
Official title: A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures
Funded at Buck Institute for Research on Aging · NIH-11126840 · Data updated 2026-11-12
A team is developing a living cell system to carry and release combinations of Alzheimer's medicines directly where they're needed for people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Buck Institute for Research on Aging NIH-funded |
| Lab location | 1 site (Novato, United States) |
| Project start | September 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $914,477 |
| NIH project number | 4R01AG081989-04 |
| Project ID | NIH-11126840 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with early-to-moderate Alzheimer's disease who are open to providing biological samples or taking part in future clinical studies would be the most likely candidates.
✕Less likely to help
People without Alzheimer's or those with very advanced dementia unlikely to respond to disease-modifying treatments may not see direct benefit from this work.
What this research studies
Researchers are building living cells that can carry multiple Alzheimer's drugs, move to affected areas in the brain, and release medicine only when and where it's needed. The design aims to target three key problems in Alzheimer's—amyloid, tau, and harmful inflammation—while cutting down on side effects from giving many drugs at once. The work uses laboratory models to test whether this platform can protect antibodies and other drugs from causing toxicities when combined. If lab results are promising, the approach could move toward studies that involve people or donated patient samples.
Why it matters
Potential benefit: If successful, this could allow safer and more effective combination treatments for Alzheimer's by focusing drug action on diseased brain regions and lowering overall side effects.
How similar studies have gone: Some antibody drugs have reduced amyloid in early Alzheimer's but showed limited clinical benefit, and using cell-based targeted delivery for combination therapy is largely new and untested in humans.
Where this research is happening
-
Buck Institute for Research on Aging
Novato, United States Active
Researchers
- Principal investigator: Andersen, Julie Kay — Buck Institute for Research on Aging
- Study coordinator: Andersen, Julie Kay
Related research
Other NIH-funded projects on the same topics.
-
Alzheimer’s disease and related brain changes linked to chemicals in the body
This NIH grant supports a patient-centered effort to map how environmental exposures and body chemistry relate to Alzheimer’s disease and related dementias.
-
Understanding how everyday exposures affect Alzheimer's disease progression
A national research effort is studying how environmental exposures, gut health, diet, and metabolism relate to Alzheimer's and related dementias to identify new ways to diagnose and treat these conditions.
-
How environment, gut health, and metabolism affect Alzheimer’s disease
This grant looks at how environmental exposures, gut microbes, diet, and metabolism influence Alzheimer’s disease and related dementias.
-
Understanding how chemical exposures affect Alzheimer's disease progression
This project studies how environmental chemicals and other biological factors influence brain health and the course of Alzheimer’s disease and related dementias.
-
Understanding how brain hyperexcitability and sex differences affect Alzheimer’s disease
This grant tests whether brain hyperexcitability linked to a genetic risk (APOE4) and sex differences contribute to memory decline in Alzheimer’s disease, using computer simulations and mouse data to guide potential human treatments.
-
CNS Exosomes and Adaptive Immunity in Alzheimer’s Disease
This project studies how tiny brain vesicles called exosomes may activate the body's immune system in Alzheimer’s disease, with the goal of understanding mechanisms that could lead to new treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.